Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

BIIB122

Source date not recordedAnalyse record ↗

LRRK2 inhibitor continuing in Phase 2a biomarker research for genetically defined Parkinson's disease after the idiopathic program was discontinued.

Modality
oral small-molecule LRRK2 kinase inhibitor
Availability (US)
Phase 2a BEACON study Active, not recruiting in LRRK2-variant Parkinson's disease; idiopathic-Parkinson's development discontinued
Biomarkers
treatment-emergent adverse events; plasma pS935-LRRK2; blood and CSF phosphorylated Rab10; pharmacokinetics
Hallmark targeted
lysosomal dysfunction, impaired autophagy and mitophagy, neurodegeneration
Kind
investigational drug
Clinical trials
NCT06602193 — Phase 2, Active, not recruiting on May 27, 2026 update; NCT05348785 — Phase 2 LUMA, Completed; NCT05418673 — Phase 3 LIGHTHOUSE, Terminated